

Oregon Prescription Drug Monitoring Program Advisory Commission

January 17, 2025 1:00 PM Meeting Minutes

Meeting Contact: Stephanie Vesik, Stephanie.g.vesik@oha.oregon.gov, 971-200-9463

Advisory Commission Attendees:

Laura Armstrong, OD, MEd, FAAO – Chair, Optometrist, representing the Board of Optometry and Oregon Optometric Physicians Association
Katie Zinno – Public member and patient advocate, living with chronic diseases
John Hinton, DO, MPH – Physician, representing Osteopathic Physicians and Surgeons of Oregon
Maureen McAvoy Jemison – Public member with expertise in information technology
Dan Kennedy – Oregon State Pharmacy Association
Tracy Klein - PhD, FNP, Representing Oregon Nurses Association

OHA Staff Attendees:

Laura Chisholm – Section Manager, Injury and Violence Prevention
Stephanie Vesik– Compliance Officer, overseeing pharmacy compliance and user registration
Tamara Ramirez – PDMP Operations and Coordination Specialist
Bryan Loy – Research Analyst, PDMP Data Stewardship
Ariane Erickson – Research Analyst, overseeing quarterly and annual metrics for PDMP.
Elizabeth McCarthy – Overdose Epidemiologist and PDMP Epidemiologist

1. Introductions

Armstrong began the meeting with introductions. Each participant introduced themselves and their relation to the commission and the work.

2. Review of Previous Meeting's Minutes

After the introductions, Armstrong moved on to the review of the minutes from the previous meeting on January 17, 2025. Minutes from the previous meeting were reviewed. John Hinton seconded an approval. The Advisory Commission approved the minutes with no objections.

3. PDMP Overview and Discussion

Following introductions of all present and reviewing the minutes it was noted there were no members of the public on the call and an overview and general discussion of the purpose of the PDMP was decided to be unnecessary.

4. Standing Agenda Items

a. Quarterly Metrics

Review quarterly metrics, presented by Ariane Erickson, for the third quarter of 2024. Discussion began with PDMP Prescriber Enrollment: 87% of all prescribers enrolled; 99% of top prescribers. In discussion of PDMP usage trends it was noted that there was a decrease in web portal usage declined, while automated queries increased and overall report viewing increased. Discussion of prescription trends indicated an overall prescription volume increased of 4.1% during Q4, 2024, with gabapentin remained most prescribed controlled substance. There were notable increases in stimulant prescribing (amphetamine +8.1%, methylphenidate +11.3%).

b. Pharmacy and System User Compliance

Stephanie Vesik presented on recent pharmacy and system user compliance efforts made by the PDMP. During Q4, 2024 approximately 800 inactive users had their account deactivated while there were continued efforts made with the licensing boards to improve required registration rates.

The Advisor Commission was given a briefing on the January 1, 2025 start date for the collecting of schedule V and veterinary drugs.

c. Research Study Update

Bryan Loy provided the Advisory Commission with a research study update. Bryan shared that there were 6 active studies with 2 under review. To date there have been 32 publications using PDMP data. Recent study requests focus on stimulant-related health outcomes and that that was noted since 2020 there has been a marked increase in stimulant prescribing.

d. Advisory Subcommittee Update

An update on the PDMP advisory subcommittee activities was provided by Liz McCarthy. After a brief refresher on the subcommittees activities of providing educational information to those prescribers meeting “risky prescribing” metrics. She further shared the subcommittee chose a new “Tri-prescribing” measure introduced (opioid + sedative + stimulant) that will result in new educational materials being sent to those prescribers. It is expected to be a small number of prescribers who meet this metric. Liz further shared that the subcommittee in the future will be looking at “patient-centered tri-prescribing” measures, and reassured the Advisory Commission that the subcommittee’s goal remains educational, not punitive.

5. PDMP Stimulant Dashboard Demonstration

Bryan Loy presented a special report on Stimulants & Health Outcomes.

The report presented was prepared under the Harold Rogers grant with an intention to describe and observe the role of stimulants on negative health outcomes. Findings presented included:

- High death rates with co-prescriptions of stimulants and benzodiazepines.
- Modafinil was linked to highest hospitalization and death rates, ranging from 94 per 10,000 to 126 per 10,000, depending on the stimulant prescribing practice, approximately 1% of those receiving Modafinil prescriptions.
- Older adults using high-quantities of stimulants showed elevated health risks.

Bryan presented a discussion of the limitations of this observational research including causality not proven, small sample sizes, and that the data sets involved are administrative in nature.

6. 2025 Implementation Updates

Stephanie Vesik informed the advisory commission of the January 1, 2025 implementation of the legislation requiring the reporting of Schedule V Controlled Substances and veterinary drug dispensations from retail pharmacies. In addition to the legislatively mandated new fields Oregon also began collecting data on the date a prescription is sold. PDMP staff are monitoring the incoming of these new data fields looking for any unexpected issues.

Stephanie announced that after many years of efforts that reciprocal data sharing with California began January 2, 2025. The Advisory Commission was informed one of the stipulations of the agreement was that all providers are required to sign and retain a data disclosure agreement with California. The Commission was reminded that Oregon is already sharing with Washington, Idaho, Nevada, Arizona, Texas, and continuing to work on adding the remaining Western States, Alaska, Utah, and Colorado. Once the Western region states are added then the PDMP will consider the benefit of adding additional states.

7. Old Business

Tribal Data Sharing was discussed by Bryan Loy who shared that during the current 2025 legislative session Senate Bill 841 was introduced to enable data sharing with Oregon's tribes and tribal epicenter to obtain PDMP data for research purposes. This legislation supports tribal public health through respectful data agreements. Bryan shared in these types of data agreements he would do the data linkage work and return deidentified data to the requesting entity.

The Advisory Commission had some discussion the Tribal entities request for this data and their inclusion in the discussion on the drafting of the bill. Laura Chisholm was able to discuss the inclusion of the Tribes in question had an active participating role in the many discussions leading up to the drafting of the bill, as well as Oregon Department of Justice counsel, and the Tribal Liaison for Oregon Public Health. Laura

assured the Commission that the tribal entities were in support of the legislation and that it respected their tribal sovereignty.

The Advisory Commission was advised the bill had only dropped within the legislation and was inquired on their support, neutrality, or concern about this legislation.

Laura Armstrong brought the matter of support to a vote among the advisory commission. There was some discussion among the commission members regarding their understanding of the bill. Advisory commission members had questions regarding tribal involvement and data collection. Stephanie Vesik informed the Advisory Commission that entities identified as Indian Health Services outpatient pharmacies or pharmacies on tribal lands were required under Federal legislation to report to the PDMP in the state of residency. While there was general support for the idea of the legislation and a vote of neutrality.

8. New Business

There was no new business discussed by the Advisory Commission during this meeting.

9. Open Issues

The Advisory Commission has two open seats, one with the Oregon Medical Association and another for another public member. Members of the commission were encouraged to do what they can to encourage the appropriate parties to fill those seats.

10. Public Comment

No public joined or made comment during this meeting.

11. Next Meeting Date: July 18, 2025, 1pm PST

12. Member Wrap-Up

13. Adjournment by Laura Armstrong at 1:54pm